TP53 and cancer: Clonal evaluation of altered genes led to a proposed oncogenic model of cancer progression initiated by deletion of NKX3-1 or FOXP1 and TMPRSS2-ERG fusion, followed by CDKN1B or TP53 alterations and finally ending in PTEN loss.